Inhaled Nitric Oxide

SOL #: W81K00-26-Q-A126Sources Sought

Overview

Buyer

DEPT OF DEFENSE
Dept Of The Army
W40M MRC0 WEST
JBSA FT SAM HOUSTON, TX, 78234-4504, United States

Place of Performance

DWG, TX

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Timeline

1
Posted
Apr 8, 2026
2
Response Deadline
Apr 15, 2026, 2:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Medical Readiness Contracting Office-West (MRCO-W), JBSA, Fort Sam Houston, Texas, is conducting a Sources Sought to identify potential sources for an Inhaled Nitric Oxide Gas contract in support of the Respiratory Department at Brooke Army Medical Center (BAMC). This market research aims to determine if the effort can be successfully competed and/or set-aside for Small Businesses. Responses are due April 15, 2026.

Scope of Work

This requirement is for the purchase of inhaled Nitric Oxide (iNO) to improve oxygenation for patients undergoing various procedures at BAMC. The iNO must adhere to the salient characteristics outlined in Attachment (1), which include:

  • Acting as a selective pulmonary vasodilator to improve oxygenation and blood flow.
  • Compatibility with ventilatory support therapies.
  • Continuous monitoring of inspired NO, NO2, and O2 levels.
  • Prevention of NO2 generation exceeding 20 ppm.
  • Inclusion of a backup battery and reserve delivery system.
  • Meeting all U.S. Food and Drug Administration (FDA) specifications.
  • Gas specifications: blend of nitric oxide and nitrogen, available in 800 ppm or 100 ppm concentrations, supplied in aluminum cylinders.

Contract & Timeline

  • Type: Sources Sought / Market Research
  • NAICS Code: 325413 – In-Vitro Diagnostics Substance Manufacturing (Size Standard: 1,250 employees)
  • Period of Performance: One (1) base year (01 JAN 2027 – 31 DEC 2027) plus four (4) option years (01 JAN 2028 - 31 DEC 2032).
  • Set-Aside: None specified; market research to determine potential for Small Business set-asides (including 8(a), Service-Disabled Veteran-Owned, HubZone, and Women-Owned).
  • Response Due: April 15, 2026, 2:00 PM Z
  • Published: April 8, 2026, 6:10 PM Z

Evaluation

Responses will be used for planning purposes only to determine the best acquisition strategy and potential for small business participation. This is not a solicitation, and responses do not guarantee future participation or contract awards.

Additional Notes

Interested parties should email responses to Jaclyn Evans at jaclyn.v.evans.civ@health.mil. The Government will not reimburse any expenses associated with preparing or participating in this research.

People

Points of Contact

James M DavisSECONDARY

Files

Files

Download

Versions

Version 1Viewing
Sources Sought
Posted: Apr 8, 2026
Inhaled Nitric Oxide | GovScope